Protagonist Therapeutics, Inc. Logo

Protagonist Therapeutics, Inc.

PTGX

(1.0)
Stock Price

41,49 USD

27.65% ROA

34.68% ROE

15.86x PER

Market Cap.

2.589.446.216,00 USD

2.52% DER

0% Yield

52.76% NPM

Protagonist Therapeutics, Inc. Stock Analysis

Protagonist Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Protagonist Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (105.89%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

3 ROA

The stock's ROA (-40.99%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's elevated P/BV ratio (3292.63x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Protagonist Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Protagonist Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Protagonist Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Protagonist Therapeutics, Inc. Revenue
Year Revenue Growth
2014 0
2015 0 0%
2016 0 0%
2017 20.063.000 100%
2018 30.925.000 35.12%
2019 231.000 -13287.45%
2020 28.628.000 99.19%
2021 27.357.000 -4.65%
2022 26.581.000 -2.92%
2023 0 0%
2023 60.000.000 100%
2024 16.668.000 -259.97%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Protagonist Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2014 7.459.000
2015 11.831.000 36.95%
2016 25.705.000 53.97%
2017 46.181.000 44.34%
2018 59.497.000 22.38%
2019 65.003.000 8.47%
2020 74.506.000 12.75%
2021 126.006.000 40.87%
2022 126.215.000 0.17%
2023 122.656.000 -2.9%
2023 120.161.000 -2.08%
2024 134.080.000 10.38%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Protagonist Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 1.860.000
2015 2.963.000 37.23%
2016 6.961.000 57.43%
2017 11.779.000 40.9%
2018 13.697.000 14%
2019 15.749.000 13.03%
2020 18.638.000 15.5%
2021 27.196.000 31.47%
2022 31.739.000 14.31%
2023 30.648.000 -3.56%
2023 33.491.000 8.49%
2024 37.760.000 11.31%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Protagonist Therapeutics, Inc. EBITDA
Year EBITDA Growth
2014 -7.292.000
2015 -14.464.000 49.59%
2016 -27.947.000 48.24%
2017 -37.897.000 26.26%
2018 -42.269.000 10.34%
2019 -77.709.000 45.61%
2020 -63.662.000 -22.06%
2021 -125.551.000 49.29%
2022 -131.373.000 4.43%
2023 -153.304.000 14.31%
2023 -90.340.000 -69.7%
2024 -151.604.000 40.41%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Protagonist Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
2014 0
2015 -247.000 100%
2016 -317.000 22.08%
2017 20.063.000 101.58%
2018 30.925.000 35.12%
2019 231.000 -13287.45%
2020 28.628.000 99.19%
2021 24.582.000 -16.46%
2022 25.549.000 3.78%
2023 0 0%
2023 56.688.000 100%
2024 13.100.000 -332.73%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Protagonist Therapeutics, Inc. Net Profit
Year Net Profit Growth
2014 -11.072.000
2015 -14.858.000 25.48%
2016 -37.177.000 60.03%
2017 -36.957.000 -0.6%
2018 -38.924.000 5.05%
2019 -77.187.000 49.57%
2020 -66.150.000 -16.68%
2021 -122.627.000 46.06%
2022 -123.413.000 0.64%
2023 -136.420.000 9.53%
2023 -78.955.000 -72.78%
2024 -122.464.000 35.53%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Protagonist Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 -2
2015 -3 50%
2016 -6 60%
2017 -2 -150%
2018 -2 -100%
2019 -3 50%
2020 -2 -100%
2021 -3 50%
2022 -3 0%
2023 -2 0%
2023 -1 -100%
2024 -2 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Protagonist Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
2014 -8.042.000
2015 -14.784.000 45.6%
2016 -30.351.000 51.29%
2017 3.206.000 1046.69%
2018 -50.433.000 106.36%
2019 -42.494.000 -18.68%
2020 -72.955.000 41.75%
2021 -108.966.000 33.05%
2022 -108.932.000 -0.03%
2023 -70.845.000 -53.76%
2023 -27.015.000 -162.24%
2024 268.594.000 110.06%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Protagonist Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2014 -7.743.000
2015 -14.385.000 46.17%
2016 -29.972.000 52.01%
2017 3.872.000 874.07%
2018 -49.947.000 107.75%
2019 -41.527.000 -20.28%
2020 -72.484.000 42.71%
2021 -107.865.000 32.8%
2022 -108.137.000 0.25%
2023 -70.236.000 -53.96%
2023 -26.611.000 -163.94%
2024 268.622.000 109.91%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Protagonist Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2014 299.000
2015 399.000 25.06%
2016 379.000 -5.28%
2017 666.000 43.09%
2018 486.000 -37.04%
2019 967.000 49.74%
2020 471.000 -105.31%
2021 1.101.000 57.22%
2022 795.000 -38.49%
2023 609.000 -30.54%
2023 404.000 -50.74%
2024 28.000 -1342.86%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Protagonist Therapeutics, Inc. Equity
Year Equity Growth
2014 7.955.000
2015 9.596.000 17.1%
2016 -64.593.000 114.86%
2017 -101.550.000 36.39%
2018 -140.474.000 27.71%
2019 -217.661.000 35.46%
2020 -283.811.000 23.31%
2021 -409.362.000 30.67%
2022 -536.755.000 23.73%
2023 -643.045.000 16.53%
2023 336.677.000 291%
2024 541.324.000 37.8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Protagonist Therapeutics, Inc. Assets
Year Assets Growth
2014 10.328.000
2015 14.845.000 30.43%
2016 93.990.000 84.21%
2017 163.734.000 42.6%
2018 139.472.000 -17.4%
2019 154.917.000 9.97%
2020 324.468.000 52.26%
2021 347.695.000 6.68%
2022 247.928.000 -40.24%
2023 330.016.000 24.87%
2023 357.951.000 7.8%
2024 614.629.000 41.76%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Protagonist Therapeutics, Inc. Liabilities
Year Liabilities Growth
2014 2.373.000
2015 5.249.000 54.79%
2016 6.435.000 18.43%
2017 43.102.000 85.07%
2018 26.957.000 -59.89%
2019 74.953.000 64.03%
2020 44.862.000 -67.07%
2021 47.674.000 5.9%
2022 784.683.000 93.92%
2023 27.867.000 -2715.81%
2023 21.274.000 -30.99%
2024 73.305.000 70.98%

Protagonist Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
5.21
Net Income per Share
2.77
Price to Earning Ratio
15.86x
Price To Sales Ratio
8.11x
POCF Ratio
11.64
PFCF Ratio
11.22
Price to Book Ratio
4.98
EV to Sales
7.03
EV Over EBITDA
14.5
EV to Operating CashFlow
9.69
EV to FreeCashFlow
9.72
Earnings Yield
0.06
FreeCashFlow Yield
0.09
Market Cap
2,59 Bil.
Enterprise Value
2,24 Bil.
Graham Number
23.47
Graham NetNet
8.02

Income Statement Metrics

Net Income per Share
2.77
Income Quality
1.36
ROE
0.85
Return On Assets
0.28
Return On Capital Employed
0.27
Net Income per EBT
0.99
EBT Per Ebit
1.16
Ebit per Revenue
0.46
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.4
Stock Based Compensation to Revenue
0.1
Gross Profit Margin
0.99
Operating Profit Margin
0.46
Pretax Profit Margin
0.53
Net Profit Margin
0.53

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
3.78
Free CashFlow per Share
3.77
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0.21
Return on Invested Capital
0.28
Return on Tangible Assets
0.28
Days Sales Outstanding
1.57
Days Payables Outstanding
392.94
Days of Inventory on Hand
0
Receivables Turnover
232.93
Payables Turnover
0.93
Inventory Turnover
3371000
Capex per Share
0.01

Balance Sheet

Cash per Share
9,20
Book Value per Share
8,83
Tangible Book Value per Share
8.83
Shareholders Equity per Share
8.83
Interest Debt per Share
0.26
Debt to Equity
0.03
Debt to Assets
0.02
Net Debt to EBITDA
-2.23
Current Ratio
13.73
Tangible Asset Value
0,54 Bil.
Net Current Asset Value
0,50 Bil.
Invested Capital
541379000
Working Capital
0,53 Bil.
Intangibles to Total Assets
0
Average Receivables
0,15 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.5
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Protagonist Therapeutics, Inc. Dividends
Year Dividends Growth

Protagonist Therapeutics, Inc. Profile

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

CEO
Dr. Dinesh V. Patel Ph.D.
Employee
126
Address
7707 Gateway Boulevard
Newark, 94560-1160

Protagonist Therapeutics, Inc. Executives & BODs

Protagonist Therapeutics, Inc. Executives & BODs
# Name Age
1 Mr. Matthew M. Gosling J.D.
Executive Vice President & General Counsel
70
2 Dr. Dinesh V. Patel Ph.D.
Chief Executive Officer, President, Secretary & Director
70
3 Mr. Asif Ali
Executive Vice President & Chief Financial Officer
70
4 Dr. Suneel K. Gupta Ph.D.
Chief Development Officer
70
5 Dr. Mark Smythe Ph.D.
Founder & Vice President Technology
70
6 Mr. Mohammad Masjedizadeh Ph.D.
Executive Vice President & Chief Technical Officer
70
7 Ms. Carena Spivey
Head of HR & Senior Vice President of Human Resources
70
8 Dr. Ashok Bhandari Ph.D.
Executive Vice President & Chief Drug Discovery and Preclinical Development Officer
70
9 Mr. Carter J. King
Executive Vice President of Business Development
70
10 Ms. Abha Bommireddi
Executive Vice President of Portfolio & Program Management
70

Protagonist Therapeutics, Inc. Competitors